TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6460587

Group type: EXPERIMENTAL
Intervention: Zimelidine (ZIM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Norzimelidine (NZIM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Zimelidine (ZIM) and Norzimelidine (NZIM)
Number of subjects: 8
Study: 31266367

Group type: EXPERIMENTAL
Intervention: Strengths intervention
Number of subjects: 22

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 22
Study: 27824428

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Internal standard (Ofloxacin)
Number of subjects: 0
Study: 25403163

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous cardiosphere‐derived cells (CDCs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard palliation alone
Number of subjects: 14
Study: 23076005

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% and epinephrine 1:1,000,000
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Local tumescent anaesthesia 0.15% TLA: ropivacaine, lidocaine, saline solution plus epinephrine 1:1,000,000
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2% Lidocaine with 20 minutes tourniquet (Control Group)
Number of subjects: 20
Study: 21781649

Group type: EXPERIMENTAL
Intervention: Roflumilast (500 μg, p.o.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Roflumilast N-oxide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 12
Study: 19303273

Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg, three times daily for four weeks)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (vitamin placebo, three times daily for four weeks)
Number of subjects: 105
Study: 17803436

Group type: EXPERIMENTAL
Intervention: brimonidine 0.2%/timolol 0.5%
Number of subjects: 30

Group type: COMPARATOR
Intervention: dorzolamide 2%/timolol 0.5%
Number of subjects: 30
Study: 15025736

Group type: EXPERIMENTAL
Intervention: RWJ‐68023 (high dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: RWJ‐68023 (low dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11811431

Group type: EXPERIMENTAL
Intervention: Nasal spectacles
Number of subjects: 255

Group type: COMPARATOR
Intervention: Hudson face mask
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Nasal spectacles (excluding male patients with abdominal surgery and muscle relaxants)
Number of subjects: 255
Study: 9745191

Group type: EXPERIMENTAL
Intervention: Isosorbide in spray 1.25 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Magnesium sulphate 4 g infused in one hour, then 1 g each hour for a maximum of five hours
Number of subjects: 36
Study: 8521205

Group type: EXPERIMENTAL
Intervention: Intravenous chlorpromazine (CPZ) 0.1 mg/kg/dose, up to three doses
Number of subjects: 91

Group type: COMPARATOR
Intervention: Intravenous metoclopramide (MC) 0.1 mg/kg/dose, up to three doses
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intravenous chlorpromazine (CPZ)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Intravenous metoclopramide (MC)
Number of subjects: 91
Study: 2920498

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pipemidic acid
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1054407

Group type: EXPERIMENTAL
Intervention: Cosmetic dentifrice
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional dentifrice
Number of subjects: 120
Study: 30726862

Group type: COMPARATOR
Intervention: Glucose 2.5 g/day (g-group) for college students
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sucrose 5 g/day (s-group) for college students
Number of subjects: 41

Group type: COMPARATOR
Intervention: Fructose 2.5 g/day (f-group) for adults
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sucrose 5 g/day (s-group) for adults
Number of subjects: 41
Study: 28244002

Group type: EXPERIMENTAL
Intervention: Health-space.net social networking intervention
Number of subjects: 347

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 347
Study: 26188394

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (Jevtana)
Number of subjects: 29

Group type: COMPARATOR
Intervention: AR-V7 positive CTCs
Number of subjects: 29
Study: 22804103

Group type: EXPERIMENTAL
Intervention: Family-to-family (FTF) program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater class attendance in FTF program
Number of subjects: 0
Study: 21531741

Group type: EXPERIMENTAL
Intervention: V‐pace mode
Number of subjects: 97
Study: 19909427

Group type: EXPERIMENTAL
Intervention: hIVIgG
Number of subjects: 12

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 12
Study: 17024939

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 with NaOCl pretreatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Prime & Bond 2.1 without NaOCl pretreatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Single Bond with NaOCl pretreatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Single Bond without NaOCl pretreatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (Prime & Bond 2.1 and Single Bond)
Number of subjects: 14
Study: 14551014

Group type: EXPERIMENTAL
Intervention: 50 microg per day E2 vaginal ring
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 100 microg per day E2 vaginal ring
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo vaginal ring
Number of subjects: 333
Study: 10701730

Group type: EXPERIMENTAL
Intervention: GM-CSF and sucralfate (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sucralfate alone (n = 20)
Number of subjects: 40
Study: 9347592

Group type: EXPERIMENTAL
Intervention: Topical anaesthetic
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 7
Study: 8409337

Group type: EXPERIMENTAL
Intervention: Roferon A 3 MU administered subcutaneously 3 times weekly after hemodialysis for 6 months
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo administered subcutaneously 3 times weekly after hemodialysis for 6 months
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Roferon A 3 MU
Number of subjects: 13
Study: 3895947

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clindamycin/tobramycin
Number of subjects: 60
Study: 30102825

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (4 μg/kg/minute for a median duration of 6.0 hours)
Number of subjects: 264
Study: 27090535

Group type: EXPERIMENTAL
Intervention: Group R (restricted view of the larynx)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Group F (full view of the larynx)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 163
Study: 24384643

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day) + ASA (325 mg/day)
Number of subjects: 838

Group type: COMPARATOR
Intervention: ASA (325 mg/day)
Number of subjects: 838
Study: 22664411

Group type: EXPERIMENTAL
Intervention: Palatable food of high caloric density
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palatable food of moderate caloric density
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palatable food of low caloric density
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-calorie food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-calorie food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-calorie food
Number of subjects: 0
Study: 20650793

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sevoflurane plus rocuronium anesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 19230215

Group type: EXPERIMENTAL
Intervention: SIT + RP
Number of subjects: 20

Group type: COMPARATOR
Intervention: SIT
Number of subjects: 20
Study: 16279582

Group type: EXPERIMENTAL
Intervention: Consumer involvement in the PRISM trial
Number of subjects: 0
Study: 12022539

Group type: EXPERIMENTAL
Intervention: Celsior solution for cardiac preservation
Number of subjects: 70
Study: 7557846

Group type: EXPERIMENTAL
Intervention: daily IFN‐alpha
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: alternate‐day IFN‐alpha
Number of subjects: 35

Group type: COMPARATOR
Intervention: no therapy (control)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: responders (treated patients)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: nonresponders (treated patients)
Number of subjects: 35

Group type: COMPARATOR
Intervention: untreated controls
Number of subjects: 35
Study: 2190251

Group type: EXPERIMENTAL
Intervention: Methylphenidate infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study: 773499

Group type: EXPERIMENTAL
Intervention: Fenoprofen
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 90
Study: 31683483

Group type: EXPERIMENTAL
Intervention: Chlorogenic Acids (CGA) beverage (553.6 mg/bottle) twice daily for 12 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 34
Study: 28961602

Group type: EXPERIMENTAL
Intervention: Video review of performance at day 3
Number of subjects: 32

Group type: COMPARATOR
Intervention: No video review of performance at day 3
Number of subjects: 32
Study: 25542620

Group type: EXPERIMENTAL
Intervention: Active care (colonoscopy at 6 months)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard care (no colonoscopy)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Active care (step-up treatment for recurrence)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Active care (no change in therapy)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Active care and Standard care
Number of subjects: 174
Study: 24800381

Group type: EXPERIMENTAL
Intervention: LGIE (Low Glycaemic Index Education)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CHDR (Conventional Healthy Dietary Recommendations)
Number of subjects: 60
Study: 21725881

Group type: EXPERIMENTAL
Intervention: Low-dose sodium aescinate (5 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-dose sodium aescinate (10 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 75
Study: 19995138

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI 80/4.5 microg x 2 inhalations (160/9 microg) twice daily
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: budesonide pMDI 80 microg x 2 inhalations (160 microg) twice daily
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: weekly recall
Number of subjects: 257

Group type: COMPARATOR
Intervention: daily recall
Number of subjects: 257
Study: 16790652

Group type: EXPERIMENTAL
Intervention: 5% Human Albumin (HA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 6% Hydroxyethyl Starch (HES)
Number of subjects: 50
Study: 14990784

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (10 mg/day for 48 weeks)
Number of subjects: 0
Study: 11006177

Group type: EXPERIMENTAL
Intervention: Prolonged coasting (withholding gonadotrophins while continuing pituitary down-regulation)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Prolonged coasting
Number of subjects: 15
Study: 9314858

Group type: EXPERIMENTAL
Intervention: Elective aneurysm repair
Number of subjects: 46
Study: 8317315

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (systemic pretreatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin (topical pretreatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline or vehicle (control)
Number of subjects: 0
Study: 3027836

Group type: EXPERIMENTAL
Intervention: Oral itraconazole (200 mg once daily for five consecutive days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2.5% selenium sulfide shampoo (once daily application for seven days)
Number of subjects: 40
Study: 29432262

Group type: EXPERIMENTAL
Intervention: Intraoperative 3-D image navigation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 49
Study: 27738639

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 28
Study: 25044383

Group type: EXPERIMENTAL
Intervention: Oral pentoxifylline 400 mg/thrice-weekly
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 22232050

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (15 mg per day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 21081728

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus sorafenib (60 mg/m² doxorubicin every 21 days + 400 mg sorafenib twice daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Doxorubicin alone (60 mg/m² doxorubicin every 21 days + placebo)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus sorafenib
Number of subjects: 96

Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 96
Study: 18425403

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) measured by accelerometers and lower extremity strength by a jump-and-reach test in boys (n = 128)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Physical activity (PA) measured by accelerometers and lower extremity strength by a jump-and-reach test in girls (n = 141)
Number of subjects: 269
Study: 15804468

Group type: COMPARATOR
Intervention: Tower Trainer
Number of subjects: 46

Group type: COMPARATOR
Intervention: LapSim
Number of subjects: 46
Study: 12909072

Group type: EXPERIMENTAL
Intervention: Ventricular rate control
Number of subjects: 252

Group type: COMPARATOR
Intervention: Cardioversion and maintenance of sinus rhythm
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 252

Group type: COMPARATOR
Intervention: Rhythm control
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 252
Study: 10471824

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cystic fibrosis neutrophils
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cystic fibrosis monocytes
Number of subjects: 0
Study: 8966144

Group type: EXPERIMENTAL
Intervention: Bradykinin level in bronchoalveolar lavage fluid (BAL) in patients with extrinsic allergic alveolitis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 12
Study: 1920269

Group type: EXPERIMENTAL
Intervention: Continuing education courses
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Written materials and videotapes by mail
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Written materials by mail
Number of subjects: 662

Group type: COMPARATOR
Intervention: No Education Group (Control)
Number of subjects: 662
Study: 6314661

Group type: EXPERIMENTAL
Intervention: Combined therapy (surgical and drug therapy including CCNU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levomycetin as part of combined therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (cancer patients not receiving combined therapy)
Number of subjects: 0
Study: 30797722

Group type: EXPERIMENTAL
Intervention: Mobile device application (app) for drug preparation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Infusion‐rates table
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Mobile device application (app)
Number of subjects: 128
Study: 27869312

Group type: EXPERIMENTAL
Intervention: Biofeedback‐assisted pelvic muscle therapy (BAPFMT) with the MAPLe
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (toilet behavior and lifestyle instructions)
Number of subjects: 58
Study: 25476993

Group type: EXPERIMENTAL
Intervention: Low-dose total skin electron beam therapy (12 Gy, 1 Gy per fraction over 3 weeks)
Number of subjects: 33
Study: 23769122

Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21707601

Group type: EXPERIMENTAL
Intervention: Oral intervention
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: T/K intervention
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined intervention (oral+T/K)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 19538914

Group type: EXPERIMENTAL
Intervention: Parent-based intervention (PBI)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Intervention as usual (alcohol fact sheet for parents)
Number of subjects: 724
Study: 16434253

Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation
Number of subjects: 40
Study: 14716800

Group type: EXPERIMENTAL
Intervention: Cystatin C gene polymorphism + 148 GG genotype (n = 263)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Cystatin C gene polymorphism + 148 GA genotype (n = 147)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Cystatin C gene polymorphism + 148 AA genotype (n = 20)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Cystatin C gene polymorphism -82 C allele homozygotes
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Smoking history
Number of subjects: 424
Study: 11606448

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily for 12 months)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (identically appearing tablets daily for 12 months)
Number of subjects: 85
Study: 9219507

Group type: EXPERIMENTAL
Intervention: UFT at 12 mg/kg daily for 1 year
Number of subjects: 224
Study: 8489058

Group type: EXPERIMENTAL
Intervention: Fentanyl at 3 ng/ml
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Fentanyl at 10 ng/ml
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Fentanyl at 1.67 ng/ml
Number of subjects: 77

Group type: COMPARATOR
Intervention: No fentanyl (control group)
Number of subjects: 77
Study: 2893561

Group type: EXPERIMENTAL
Intervention: Sufentanil 5.0 micrograms
Number of subjects: 240
Study: 29317362

Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion Block prior to Pulsed Radiofrequency (DRG-PRF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dorsal Root Ganglion Pulsed Radiofrequency (DRG-PRF) without DRG block
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of DRG-PRF
Number of subjects: 60
Study: 28418750

Group type: EXPERIMENTAL
Intervention: Asian/Pacific Islander women
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Asian American women
Number of subjects: 318
Study: 26226938

Group type: EXPERIMENTAL
Intervention: Active HD-tDCS (2 mA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (sham HD-tDCS)
Number of subjects: 24
Study: 23625113

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg once daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg once daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 25
Study: 21436152

Group type: EXPERIMENTAL
Intervention: Falls-related self-efficacy assessed using the Activities-specific Balance Confidence Scale
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Activities-specific Balance Confidence Scale
Number of subjects: 135
Study: 18958561

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 42

Group type: COMPARATOR
Intervention: Radiochemotherapy (5-fluorouracil 200 mg/m2/day and 5040 Gy radiotherapy)
Number of subjects: 42
Study: 16874148

Group type: EXPERIMENTAL
Intervention: Weekend warrior (n=13, two sessions per week on consecutive days, 75 min each, intensity 90% of the anaerobic threshold)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Regular training (n=12, five sessions per week, 30 min each, same intensity as weekend warrior)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (n=13, no training)
Number of subjects: 38
Study: 12819941

Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) administered as a constant 72-h i.v. infusion every 2 weeks at a dose of 47 microg/m2 per hour
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) administered at 59 microg/m2 per hour
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) administered at lower doses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) administered at 47 microg/m2 per hour
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) administered at various dose levels
Number of subjects: 20
Study: 11055449

Group type: EXPERIMENTAL
Intervention: Day Hospital (DH)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Traditional Outpatient Programs (OP)
Number of subjects: 668
Study: 9387348

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Physical treatment (Group B)
Number of subjects: 62
Study: 1432282

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg/kg/dose, given in three doses 8 hours apart, final dose 1 hour before extubation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (normal saline, equal volume to dexamethasone)
Number of subjects: 51
Study: 2857212

Group type: EXPERIMENTAL
Intervention: Cyclosporin (Cy) for 90 days followed by azathioprine and prednisolone (Aza and P)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (Aza and P from day 0)
Number of subjects: 86
Study: 30563758

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus manipulation (n=31)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional treatment (n=30)
Number of subjects: 61
Study: 30286342

Group type: EXPERIMENTAL
Intervention: Exercise programme (24-week duration)
Number of subjects: 0
Study: 27441475

Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC) plus usual care
Number of subjects: 199

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 199
Study: 25171133

Group type: EXPERIMENTAL
Intervention: Oral loading of sodium valproate (20 mg/kg oral single-dose on the first day, then 10-15 mg/kg daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous loading of sodium valproate (20 mg/kg intravenous injection on the first day, then 10-15 mg/kg orally)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral maintenance administration of sodium valproate (15-20 mg/kg daily from the beginning)
Number of subjects: 90